Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

Rodica Anghel, Alexander Bachmann, Meral Bekşac, Thomas Brodowicz, Jindřich Finek, Radko Komadina, Krzysztof Krzemieniecki, I. Láng, Jozef Marencak, Roger Von Moos, Martin Pecherstorfer, Tamara Rordorf, Damir Vrbanec, Christoph Zielinski

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Summary: Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.

Original languageEnglish
Pages (from-to)439-447
Number of pages9
JournalWiener Klinische Wochenschrift
Volume125
Issue number15-16
DOIs
Publication statusPublished - Aug 2013

Fingerprint

zoledronic acid
Bone Diseases
Expert Testimony
Diphosphonates
Bone Neoplasms
Osteonecrosis
Hypocalcemia
Incidence
Jaw
Chronic Renal Insufficiency
Guidelines
Kidney
Denosumab
Research
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Anti-resorptive agents
  • Bisphosphonates
  • Denosumab
  • Metastatic breast cancer
  • Metastatic prostate cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. / Anghel, Rodica; Bachmann, Alexander; Bekşac, Meral; Brodowicz, Thomas; Finek, Jindřich; Komadina, Radko; Krzemieniecki, Krzysztof; Láng, I.; Marencak, Jozef; Von Moos, Roger; Pecherstorfer, Martin; Rordorf, Tamara; Vrbanec, Damir; Zielinski, Christoph.

In: Wiener Klinische Wochenschrift, Vol. 125, No. 15-16, 08.2013, p. 439-447.

Research output: Contribution to journalArticle

Anghel, R, Bachmann, A, Bekşac, M, Brodowicz, T, Finek, J, Komadina, R, Krzemieniecki, K, Láng, I, Marencak, J, Von Moos, R, Pecherstorfer, M, Rordorf, T, Vrbanec, D & Zielinski, C 2013, 'Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease', Wiener Klinische Wochenschrift, vol. 125, no. 15-16, pp. 439-447. https://doi.org/10.1007/s00508-013-0385-4
Anghel, Rodica ; Bachmann, Alexander ; Bekşac, Meral ; Brodowicz, Thomas ; Finek, Jindřich ; Komadina, Radko ; Krzemieniecki, Krzysztof ; Láng, I. ; Marencak, Jozef ; Von Moos, Roger ; Pecherstorfer, Martin ; Rordorf, Tamara ; Vrbanec, Damir ; Zielinski, Christoph. / Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. In: Wiener Klinische Wochenschrift. 2013 ; Vol. 125, No. 15-16. pp. 439-447.
@article{1aeb449e257c4e318e4f0797e88f4367,
title = "Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease",
abstract = "Summary: Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.",
keywords = "Anti-resorptive agents, Bisphosphonates, Denosumab, Metastatic breast cancer, Metastatic prostate cancer",
author = "Rodica Anghel and Alexander Bachmann and Meral Bekşac and Thomas Brodowicz and Jindřich Finek and Radko Komadina and Krzysztof Krzemieniecki and I. L{\'a}ng and Jozef Marencak and {Von Moos}, Roger and Martin Pecherstorfer and Tamara Rordorf and Damir Vrbanec and Christoph Zielinski",
year = "2013",
month = "8",
doi = "10.1007/s00508-013-0385-4",
language = "English",
volume = "125",
pages = "439--447",
journal = "Wiener Klinische Wochenschrift",
issn = "0043-5325",
publisher = "Springer Wien",
number = "15-16",

}

TY - JOUR

T1 - Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

AU - Anghel, Rodica

AU - Bachmann, Alexander

AU - Bekşac, Meral

AU - Brodowicz, Thomas

AU - Finek, Jindřich

AU - Komadina, Radko

AU - Krzemieniecki, Krzysztof

AU - Láng, I.

AU - Marencak, Jozef

AU - Von Moos, Roger

AU - Pecherstorfer, Martin

AU - Rordorf, Tamara

AU - Vrbanec, Damir

AU - Zielinski, Christoph

PY - 2013/8

Y1 - 2013/8

N2 - Summary: Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.

AB - Summary: Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.

KW - Anti-resorptive agents

KW - Bisphosphonates

KW - Denosumab

KW - Metastatic breast cancer

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84883349285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883349285&partnerID=8YFLogxK

U2 - 10.1007/s00508-013-0385-4

DO - 10.1007/s00508-013-0385-4

M3 - Article

C2 - 23832237

AN - SCOPUS:84883349285

VL - 125

SP - 439

EP - 447

JO - Wiener Klinische Wochenschrift

JF - Wiener Klinische Wochenschrift

SN - 0043-5325

IS - 15-16

ER -